Ming Kai Lam

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

Clemens von Birgelen, Hanim Sen, Ming Kai Lam et al. · The Lancet · 2013 · 198 citations

Dutch Peers, Percutaneous Coronary Intervention, Thrombosis +13

Fractional Flow Reserve and Coronary Bifurcation Anatomy

Shengxian Tu, Mauro Echavarría‐Pinto, Clemens von Birgelen et al. · JACC: Cardiovascular Interventions · 2015 · 78 citations · Full text

Fractional Flow Reserve, Fluid Mechanics, Physiology +5

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents

Kenneth Tandjung, Hanim Sen, Ming Kai Lam et al. · Journal of the American College of Cardiology · 2013 · 70 citations · Full text

Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents

Hanim Sen, Ming Kai Lam, Marije M. Löwik et al. · JACC: Cardiovascular Interventions · 2015 · 44 citations · Full text

Endovascular Technique, Cardiovascular Disease, Medicine +11

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial

Ming Kai Lam, Kenneth Tandjung, Hanim Sen et al. · EuroIntervention · 2015 · 24 citations · Full text